A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation

NCT06667544 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

152

Enrollment

INDUSTRY

Sponsor class

Conditions

KRAS G12D Mutation

Interventions

DRUG: RNK08954-01

Sponsor

Ranok Therapeutics (Hangzhou) Co., Ltd.